Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

NCT02953678 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02953678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02953678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
December 30, 2016
Completion date
August 14, 2019
Enrollment
71 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host disease (gvhd)